Preincubation of pituitary tumor cells with the epidrugs zebularine and trichostatin a are permissive for retinoic acid-Augmented expression of the BMP-4 and D2R genes

Endocrinology

Volumn 154, Issue 5, 2013, Pages 1711-1721

  Yacqub Usman, Kiren ^a   Duong, Cuong V ^a   Clayton, Richard N ^a   Farrell, William E ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; DOPAMINE 2 RECEPTOR; NOGGIN; RETINOIC ACID; SMALL INTERFERING RNA; TRICHOSTATIN A; ZEBULARINE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CPG ISLAND; EPIGENETICS; GENE EXPRESSION; HISTONE MODIFICATION; METHYLATION; NONHUMAN; PITUITARY TUMOR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR CELL;

ADENOMA; ANIMALS; BONE MORPHOGENETIC PROTEIN 4; CELL CULTURE TECHNIQUES; CYTIDINE; DRUG SYNERGISM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; PITUITARY NEOPLASMS; PRODRUGS; RECEPTORS, DOPAMINE D2; TIME FACTORS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 84876755543     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1061     Document Type: Article

References (35)

1. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011;7:257-266.
2. Yacqub-Usman K, Richardson A, Duong CV, Clayton RN, Farrell WE. The pituitary tumour epigenome: aberrations and prospects for targeted therapy. Nat Rev Endocrinol. 2012;8:486-494.
3. Vandeva S, Jaffrain-ReaML,Daly AF, TichomirowaM,Zacharieva S, Beckers A. The genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2010;24:461-476.
4. Páez-Pereda M, Kovalovsky D, Hopfner U, et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest. 2001;108: 1123-1131.
5. Angioni AR, Lania A, Cattaneo A, Beck-Peccoz P, Spada A. Effects of chronic retinoid administration on pituitary function. J Endocrinol Invest. 2005;28:961-964.
6. Labeur M, Paez-Pereda M, Arzt E, Stalla GK. Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas. Rev Endocr Metab Disord. 2009;10:103-109.
7. Giacomini D, Páez-Pereda M, Theodoropoulou M, et al. Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology. 2006;147: 247-256.
8. Paez-Pereda M, Giacomini D, Refojo D, et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci U S A. 2003;100:1034-1039.
9. Yacqub-Usman K, Duong CV, Clayton RN, Farrell WE. Epigenomic silencing of the BMP-4 gene in pituitary adenomas: a po-tential target for epidrug-induced re-expression. Endocrinology. 2012;153:3603-3612.
10. Takeda M, Otsuka F, Suzuki J, et al. Involvement of activin/BMP system in development of human pituitary gonadotropinomas and nonfunctioning adenomas. Biochem Biophys Res Commun. 2003; 306:812-818.
11. Bondioni S, Angioni AR, Corbetta S, et al. Effect of 9-cis retinoic acid on dopamineD2receptor expression in pituitaryadenomacells. Exp Biol Med (Maywood). 2008;233:439-446.
12. Caccavelli L, Feron F, Morange I, et al. Decreased expression of the twoD2dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology. 1994;60:314-322.
13. Passos VQ, Fortes MA, Giannella-Neto D, Bronstein MD. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology. 2009;89:163-170.
14. Samad TA, Krezel W, Chambon P, Borrelli E. Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. Proc Natl Acad Sci U S A. 1997;94:14349-14354.
15. Al-Azzawi H, Yacqub-Usman K, Richardson A, Hofland LJ, Clayton RN, Farrell WE. Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis. Endocrinology. 2011;152:364-373.
16. Massague J. How cells read TGF-α signals. Nat Rev Mol Cell Biol. 2000;1:169-178.
17. Smith WC. TGFα inhibitors. New and unexpected requirements in vertebrate development. Trends Genet. 1999;15:3-5.
18. Bahar A, Simpson DJ, Cutty SJ, et al. Isolation and characterization of a novel pituitary tumor apoptosis gene. Mol Endocrinol. 2004; 18:1827-1839.
19. Dudley KJ, Revill K, Whitby P, Clayton RN, Farrell WE. Genomewide analysis in a murine Dnmt1 knockdown model identifies epigenetically silenced genes in primary human pituitary tumors. Mol Cancer Res. 2008;6:1567-1574.
20. Jenuwein T, Allis CD. Translating the histone code. Science. 2001; 293:1074-1080.
21. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298:1039-1043.
22. Colao A, Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol. 2011;7:267-278.
23. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93:2454-2462.
24. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94:223-230.
25. Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366: 914-924.
26. van der Pas R, de Herder WW, Hofland LJ, Feelders RA. New developments in the medical treatment of Cushing's syndrome. Endocr Relat Cancer. 2012;19:R205-R223.
27. Pecori Giraldi F, Ambrogio AG, Andrioli M, et al. Potential role for retinoic acid in patients with Cushing's disease. J Clin Endocrinol Metab. 2012;97:3577-3583.
28. Peverelli E, Mantovani G, Vitali E, et al. Filamin-A is essential for dopamine D2 receptor expression and signaling in tumorous lactotrophs. J Clin Endocrinol Metab. 2012;97:967-977.
29. Tsukamoto N, Otsuka F, Miyoshi T, et al. Functional interaction of bone morphogenetic protein and growth hormone releasing peptide in adrenocorticotropin regulation by corticotrope cells. Mol Cell Endocrinol. 2011;344:41-50.
30. Takeda M, Otsuka F, Otani H, et al. Effects of peroxisome proliferator-Activated receptor activation on gonadotropin transcription and cell mitosis induced by bone morphogenetic proteins in mouse gonadotrope L-T2 cells. J Endocrinol. 2007;194:87-99.
31. Giacomini D, Acuña M, Gerez J, et al. Pituitary action of cytokines: focus on BMP-4 and gp130 family. Neuroendocrinology. 2007;85: 94-100.
32. Tsukamoto N, Otsuka F, Miyoshi T, et al. Effects of bone morphogenetic protein (BMP) on adrenocorticotropin production by pituitary corticotrope cells: involvement of up-regulation of BMP receptor signaling by somatostatin analogs. Endocrinology. 2010; 151:1129-1141.
33. Labeur M, Páez-Pereda M, Haedo M, Arzt E, Stalla GK. Pituitary tumors: cell type-specific roles for BMP-4. Mol Cell Endocrinol. 2010;326:85-88.
34. Otsuka F, Tsukamoto N, Miyoshi T, Iwasaki Y, Makino H. BMP action in the pituitary: Its possible role in modulating somatostatin sensitivity in pituitary tumor cells. Mol Cell Endocrinol. 2012;349: 105-110.
35. Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer. 2006;106:112-119.